NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • NIHR Oxford BRC impact
    • Steering Committee
    • Promoting equality, diversity and inclusion in research
    • Current Vacancies
    • Stay in Touch
    • Contact Us
  • Research

        • Research Overview
        • Clinical Research Facility
        • Health Economics
        • Ethics in the NIHR Oxford BRC
        • Medical Statistics
        • Infections in Oxfordshire Database (IORD)
        • 15 Research Themes

        • Cancer
        • Cardiovascular Medicine
        • Digital Health from Hospital to Home
        • Gene and Cell Therapy
        • Genomic Medicine
        • Imaging
        • Inflammation across Tissues
        • Life-saving Vaccines
        • Metabolic Experimental Medicine
        • Modernising Medical Microbiology and Big Infection Diagnostics
        • Musculoskeletal
        • Preventive Neurology
        • Respiratory Medicine
        • Surgical Innovation, Technology and Evaluation
        • Translational Data Science
  • Patient and Public Involvement
    • For patients and the public
    • For researchers
    • More information
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Pre-doctoral Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • PARC Programme
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • Who Do We Work With?
    • Events
    • Further Information and Additional Resources
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > Cancer > Oxford and GSK launch £50million programme to advance novel cancer research

Oxford and GSK launch £50million programme to advance novel cancer research

28 January 2025 · Listed under Cancer, Life-saving Vaccines

3d,Illustration,Of,T,Cells,Or,Cancer,Cells
Cancer T cells (Shutterstock)

Leading NIHR Oxford Biomedical Research Centre researchers will play a key role in a major new collaboration between the University of Oxford and global biopharma company GSK to advance the understanding of how cancer develops, which could inform future development of vaccines to prevent cancer.

The £50 million GSK-Oxford Cancer Immuno-Prevention Programme leverages the complementary expertise of GSK and Oxford in the science of the immune system, vaccine development and cancer biology.

It is hoped that the insights generated through the programme into how cancer develops could inform new approaches to vaccination for cancer prevention, offering fresh hope in the fight against the disease.

The programme – which will be led by Professor Sarah Blagden in Oxford’s Department of Oncology, alongside Dr Timothy Clay and Dr Ramon Kemp at GSK – unites expertise from four departments at the University and builds on Oxford’s exceptional track record in vaccine development.

Professor Irene Tracey, Vice-Chancellor of the University of Oxford, said: “This partnership represents a step forward in cancer research. By working with GSK to unite experts in clinical trials, immuno-oncology, vaccinology and pre-cancer research from across the University of Oxford, we aim to unlock the potential of cancer vaccines and bring hope to patients worldwide.”

Professor Blagden added: “We are delighted to be collaborating with GSK in this important area of research, making sure that Oxford’s fantastic science benefits patients as quickly as possible. Working together, we will greatly accelerate translational research that could lead to the development of vaccines to prevent cancer in the future.”

Three Oxford BRC-supported researchers will be Associate Directors of the new partnership: Professor Tim Elliott, (the BRC’s Co-theme Lead for Cancer), Professor Ellie Barnes (BRC So-theme Lead for Vaccines) and Professor Simon Leedham (of the BRC’s Genomic Medicine Theme.

Evidence now shows that most cancers take years or even decades to develop, starting from normal cells to precancerous cells to cancer. Oxford has world-leading expertise in the study of precancer biology including the sequencing of neoantigens, or tumour-specific proteins that prompt the immune system to recognise cancer.

This unique focus could help target the vulnerabilities of precancerous cells through an active intervention like a vaccine or targeted medicine to prevent them from progressing to cancer.

Read more about the new Oxford-GSK cancer programme.

← Blood test developed to allow early detection of multiple cancers
Scientists create new way to predict bowel cancer risk in people with IBD →

Other news

News Categories

News by Month

See all news

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Feedback

We’d love to hear your feedback. Please contact us at [email protected]

Oxford BRC on Social Media

  • Bluesky
  • Facebook
  • LinkedIn
  • Threads
  • Twitter
  • YouTube
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2025 NIHR Oxford Biomedical Research Centre